Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...

New research explores the wide world of the positives, and potential drawbacks, of new obesity medications. And each brings a new consideration for physicians.

Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...

Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss KELOWNA, BC / ACCESS Newswire / February 5, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "L ...

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide ... treated with the maximum tolerated dose of tirzepatide achieved a 20.2% reduction in ...

Patients taking the highest dose of amycretin experienced a mean weight loss of ... And based on the data so far, amycretin ...

Before we get to our kratom dosage chart, let’s briefly examine one of the most exclusive kratom strains, Dragon kratom. This kratom strain is naturally growing only on the lush green island of ...

The Zepbound LillyDirect offers comes in a single-dose vial rather than as an auto-injector pen, also called a Zepbound pen. The vial doses available are 2.5 mg and 5 mg, which is limited compared ...